HOTH

HOTH

USD

Hoth Therapeutics Inc. Common Stock

$1.320-0.060 (-4.348%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$1.380

Kõrge

$1.410

Madal

$1.320

Maht

0.06M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

17.5M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

1.20M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $0.655Praegune $1.320Kõrge $3.8

Seotud uudised

PR Newswire

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing breakthrough therapies for metabolic, dermatologic, and...

Vaata rohkem
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
PR Newswire

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Hoth Therapeutics, Inc. (NASDAQ: HOTH) today highlighted FDA Orphan Drug Designation for HT-KIT and new preclinical data demonstrating >80%...

Vaata rohkem
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
PR Newswire

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological,...

Vaata rohkem
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
PR Newswire

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for...

Vaata rohkem
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025